Related Experiment Video
Updated: Jul 15, 2026
04:30
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
[Are drug-eluting stents dangerous?]
Edoardo De Benedetti1, Philip Urban
1Département cardiovasculaire, Hôpital de LaTour, 1217 Meyrin. edb@latour.ch
Revue Medicale Suisse
|April 21, 2007
Summary
Drug-eluting stents may increase late thrombosis risk compared to bare metal stents, but the risk is low. Appropriate patient selection and therapy are key for successful outcomes in coronary artery disease treatment.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Context:
- Drug-eluting stents (DES) have revolutionized coronary artery disease (CAD) treatment.
- Concerns exist regarding an increased risk of late stent thrombosis with DES.
- Bare metal stents (BMS) serve as a comparative benchmark.
Purpose:
- To analyze available data on the risk of late thrombosis associated with DES compared to BMS.
- To evaluate the clinical implications of this risk in patients with coronary artery disease.
- To identify optimal strategies for mitigating risks and ensuring successful DES implantation.
Summary:
- Analysis suggests a probable higher risk of late thrombosis with DES versus BMS.
- This increased risk appears to be low and does not warrant withholding DES from indicated patients.
- Complex CAD cases (long lesions, small vessels, diabetes) benefit significantly from DES despite risks.
Impact:
- DES remain a valuable tool for complex coronary artery disease, particularly in high-risk patients.
- Meticulous implantation technique and appropriate patient selection are crucial for DES safety.
- Uninterrupted dual antiplatelet therapy (aspirin and clopidogrel) for 6-12 months is vital for successful outcomes.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:18Drug Delivery: Enteral Route
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Drugs in...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...